I yderligere en randomiseret klinisk undersøgelse (BO16216) fik HER2- positive patienter og patienter med hormon- receptor positiv metastatisk brystkræft anastrozol med eller uden Herceptin.
In a further randomised clinical trial (BO16216), patients with HER2 positive and hormone receptor positive metastatic breast cancer received anastrozole with or without Herceptin.